Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	12/19/2003 3:18:09 AM
From: nigel bates	of 86

ALTANA will Submit Daxas-R (PDE4-inhibitor) for European Approval in February 2004 BAD HOMBURG, Germany--(BUSINESS WIRE)--Dec. 19, 2003--ALTANA AG , Germany, announced today that its Pharmaceutical Division ALTANA Pharma, in partnership with Pfizer Inc., will submit the registration dossier for its respiratory drug Daxas(R) (Roflumilast) for European approval to the EMEA (European Agency for the Evaluation of Medicinal Products) in February 2004. Daxas(R) is being developed as an oral, once-daily, anti-inflammatory, selective phosphodiesterase-4 (PDE4)-inhibitor for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. "We are delighted that the approval process in Europe can be initiated. The efficacy and safety of Daxas(R) will provide an important option for patients suffering from COPD and asthma", said Dr. Hans-Joachim Lohrisch, Member of the Management Board of ALTANA AG and CEO of ALTANA Pharma. Daxas(R) is being developed with Pfizer in the United States and other markets. A cooperation agreement has also been made with Tanabe Seiyaku in Japan...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next